Skip to main content
. 2023 Oct 12;15(20):4953. doi: 10.3390/cancers15204953

Figure 1.

Figure 1

Time to initiation of next chemotherapy or death (A) and overall survival (B) in 42 patients with Her-2-negative metastatic breast cancer who had received either single-agent pegylated liposomal doxorubicin (PLD) or single-agent taxane in first-line chemotherapy with subsequent crossover. Patients in group PLD (n = 23) have received first-line PLD and later taxane. Patients in group TAX (n = 19) have received first-line taxane and later PLD. p = p-value. TAX = taxane.